Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 882361 | ISIN: US5898891040 | Ticker-Symbol: MM3
Frankfurt
17.05.24
09:16 Uhr
74,50 Euro
-1,00
-1,32 %
1-Jahres-Chart
MERIT MEDICAL SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
MERIT MEDICAL SYSTEMS INC 5-Tage-Chart
RealtimeGeldBriefZeit
74,0076,5013:04
GlobeNewswire (Europe)
623 Leser
Artikel bewerten:
(2)

Merit Medical Systems, Inc.: Merit Medical Announces Process for Chief Executive Officer Succession Planning

SOUTH JORDAN, Utah, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today outlined the ongoing succession planning process for its Chief Executive Officer (CEO). Pursuant to an Amended and Restated Employment Agreement, effective June 8, 2023, Merit founder, CEO, and President, Fred Lampropoulos, will continue to serve as Merit's CEO and President through December 31, 2025.

To carry out its responsibility for CEO succession, the Merit Board of Directors appointed a special steering committee of independent directors led by Ann Millner, Ed.D., Lead Independent Director. The committee is developing and providing oversight of a succession plan in preparation for Mr. Lampropoulos' retirement. The plan is also intended to prepare the company for a CEO transition at the appropriate time. Korn Ferry, a leading executive search firm, is currently assisting Merit's Board of Directors in the process of identifying potential internal and external candidates.

"My fellow directors and I are committed to identifying a successor with the capabilities inherent to Merit's leadership requirements, including the ability to identify and pursue new strategic opportunities, attract and retain key talent, and build on the tradition of innovation that has been a hallmark of the company's success," said Dr. Millner. "We are focused on implementing a thoughtfully developed CEO succession plan that will maintain valued aspects of Merit's culture and position the company for future growth, development, and value creation."

The company does not intend to provide further updates on the process until such time as a successor is designated.

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,100 people worldwide.

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc.,?its subsidiaries, or its licensors.

CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 |?sarah.comstock@merit.com

INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
ICR Westwicke
+1-443-213-0509 |?mike.piccinino@westwicke.com


KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2023 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.